¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷ : 2022-09-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷ : 2022-09-17
±³À°ÀÏÀÚ : 2022-09-17
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : [¿Â/¿ÀÇÁ¶óÀÎ º´Çà] 2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ  
´ã´çÀÚ : °­°æ·¡
¿¬¶ôó : 02-3275-5335  
À̸ÞÀÏ : khfs3@khfs.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í ±³¼ö: 70,000¿øÀüÀÓÀÇ,Á¦¾à °ü·Ã Á¾»çÀÚ: 30,000¿ø Àü°øÀÇ, °£È£»ç, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ), ±ºÀÇ°ü: 10,000¿ø65¼¼ ÀÌ»ó, Çлý, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ): ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:00~09:15 Current status of heart transplantation in Korea with challenging case  ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:15~09:35 2022 Update on heart transplant with case discussion  Andreas Zuckermann(Medical University of Vienna, Austria) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:35~09:50 Antibody mediated rejection, what is new?  ÃÖÈ¿ÀÎ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:50~10:05 Non-invasive monitoring of rejection after heart transplantation  Josef Stehlik(University of Utah, USA) 
Åä·Ð 09-17 ±×·£µåº¼·ë 10:05~10:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-17 ±×·£µåº¼·ë 10:30~11:00 Coffee Break  () 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:00~11:20 Prevalence and cumulative risk of familial idiopathic  Ray Hershberger(The Ohio State University, USA) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:20~11:35 The state of precision cardiovascular medicine status in Korea  ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:35~11:50 Genetic basis of myocardial recovery in dilated cardiomyopathy: Potential therapeutic implications  Naveen Pereira(Mayo Clinic, USA) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:50~12:05 Contributions of sarcomere and mitochondria-related multigene variants to the endophenotype of Hypertrophic Cardiomyopathy  ÃÖÀÇ¿µ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 09-17 ±×·£µåº¼·ë 12:05~12:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
½Ä»ç 09-17 ±×·£µåº¼·ë 12:30~13:30 Lunch  () 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 13:30~13:45 Impella in advanced heart failure: Is revolutionized the field of mechanical circulatory support?  Jun Nakata(Nippon Medical School Hospital, Japan) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 13:45~14:00 Overcome for donor shortage: How to improve donor heart utilization?  ÇöÁØÈ£(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 14:00~14:15 Emergence of destination therapy in Japan  Koichiro Kinugawa(University of Toyama, Japan) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 14:15~14:30 Heart transplantation in patients with mechanical circulatory support : What should be aware of?  À̼ö¿ë(ºÎ»êÀÇ´ë) 
Åä·Ð 09-17 ±×·£µåº¼·ë 14:30~15:00 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-17 ±×·£µåº¼·ë 15:00~15:20 Coffee Break  () 
±âŸ 09-17 ±×·£µåº¼·ë 15:20~15:25 Keynote lecture (Session introduction): °³¿øÀÇÀÇ ÀÔÀå¿¡¼­ ¹Ù¶óº» ½ÉºÎÀü Àü¹®ÀÇ ¿ªÇÒ  ±èÇѼö(ºÐ´ç21¼¼±â³»°ú) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 15:25~15:40 Take 1. Heart failure diagnosis: Diagnosis of heart failure patient - Diagnostic work ( stage A to C)  È²ÀÎâ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 15:40~15:55 Take 2. Chronic heart failure management: Medical treatment - How to implement guideline directed medical treatment  ±èÇüÀ±(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 15:55~16:10 Take 3. Chronic heart failure management: Comorbidities - How to manage important comorbidities in heart failure  ÀÌÁ¤Àº(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 16:10~16:25 Take 4. Chronic heart failure Management: When to refer?  ¼º¼®¿ì(Ãæ³²ÀÇ´ë) 
Åä·Ð 09-17 ±×·£µåº¼·ë 16:25~16:50 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷ : 2022-09-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022 ´ëÇѹ̿뼺Çü·¹ÀÌÀúÀÇÇÐȸ Ãß°èÇмú´ëȸ : 2022-09-18
´ÙÀ½±Û Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç ¿¬¼ö°­Á : 2022-09-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 72 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 40 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 48 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 54 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 44 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 44 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 21 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 18 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 44 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 21 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 18 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 43 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 31 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 33 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 28 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷